概览
DIA’s mission – to work across the healthcare continuum to ensure patients receive the therapies they need – is more essential than ever during times like these. DIA acknowledges the time and effort that has gone into planning and preparing for DIA’s Pharmacovigilance Strategies Workshop, and trusts that everyone will understand the need to respond to current, evolving health concerns in a responsible manner. These precautions are being taken to ensure the health and safety of our entire, global DIA family.
DIA is committed to exploring all possible avenues to provide a productive setting and a fulfilling meeting experience. We appreciate your patience as we work through any potential challenges.
DIA has a long history of working closely with Industry and Regulators to bring topics and speakers together with broad audiences in order to create stimulating and relevant discussion.
Join the DIA Pharmacovigilance Strategies Workshop to discuss the current landscape and join intense and well-lead discussion that may help you to progress your knowledge and practices.
The conference format is designed to stimulate dialogue and generate solutions through a series of interactive sessions and workshops conducted in an informal setting allowing for in-depth discussion in smaller groups.
项目委员会
-
Wendy Huisman, PharmD Director
Vigifit, Netherlands -
Shahin Kauser Leading Senior Scientific Assessor
MHRA, United Kingdom -
Maarten Lagendijk, MSc Deputy EU QPPV
MSD, Netherlands -
Bianca Mulder, PharmD, MPharm, MSc Pharmacovigilance Assessor
Medicines Evaluation Board, Netherlands -
Elena Popa, MPharm Regulatory Policy and Innovation Lead
Bayer, Switzerland -
Francoise Sillan, MD EU1 UK QPPV
Ipsen, France -
Mette Stockner, MD Senior Pharmacovigilance Director
Savara ApS, Denmark -
Willemijn van der Spuij, MSc Executive Director, WorldWide Patient Safety International, Europe
Switzerland -
James Whitehead, MBA, MSc Senior Director, Device & Digital Safety
AstraZeneca, United Kingdom